138 related articles for article (PubMed ID: 17966148)
1. [Stop selling rosiglitazone].
Johansen K
Ugeskr Laeger; 2007 Sep; 169(36):3007. PubMed ID: 17966148
[No Abstract] [Full Text] [Related]
2. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
3. [Rosiglitazone].
Johansen K
Ugeskr Laeger; 2010 Sep; 172(38):2631; author reply 2631. PubMed ID: 20931733
[No Abstract] [Full Text] [Related]
4. [The decline of rosiglitazone].
Johansen K
Ugeskr Laeger; 2008 Mar; 170(12):1063. PubMed ID: 18401914
[No Abstract] [Full Text] [Related]
5. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
Vaccaro O; Riccardi G
Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
[No Abstract] [Full Text] [Related]
6. [Rosiglitazone--statistics for benefits and problems].
Hjelmesaeth J; Røislien J
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
[No Abstract] [Full Text] [Related]
7. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
8. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
9. The rosiglitazone controversy: the Indian perspective.
Mohan V; Joshi SR
J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
[No Abstract] [Full Text] [Related]
10. [Glitazone - mailing no 1. In response to DMW 49/2007].
Traut V
Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
[No Abstract] [Full Text] [Related]
11. [Glitazone - mailing no 3. In response to DMW 49/2007].
Gundel UF
Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
[No Abstract] [Full Text] [Related]
12. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
13. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
Håkansson J
Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
[No Abstract] [Full Text] [Related]
14. Cardiovascular risk of rosiglitazone: another perspective.
Waksman JC
J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
[TBL] [Abstract][Full Text] [Related]
15. [Glitazones more than hypoglycemics in type 2 diabetes].
Sjöholm A
Lakartidningen; 2007 Oct 24-30; 104(43):3201-3. PubMed ID: 18018938
[No Abstract] [Full Text] [Related]
16. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
17. Fracture risk is a class effect of glitazones.
Short R
BMJ; 2007 Mar; 334(7593):551. PubMed ID: 17363794
[No Abstract] [Full Text] [Related]
18. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Lehmann DF; Lohray BB
J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
[No Abstract] [Full Text] [Related]
19. [Wrong choice of antidiabetics can be disastrous].
Sjöholm A
Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2300-1. PubMed ID: 20973243
[No Abstract] [Full Text] [Related]
20. [Don't judge all glitazones alike!].
Sjöholm A
Lakartidningen; 2007 Oct 24-30; 104(43):3205. PubMed ID: 18018940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
